Abstract
Bcl-3 is an atypical member of the inhibitor of kappa light polypeptide gene enhancer in B-cells (IκB) family. It associates with p50/nuclear factor-κB1 (NF-κB1) and p52/NF-κB2 homodimers in nuclei where it modulates transcription in a context-dependent manner. A subset of B-cell tumors exhibits recurrent translocations of Bcl-3, resulting in overexpression. Elevated expression without translocations is also observed in various B-cell lymphomas and even some solid tumors. Here we investigated the role of Bcl-3 in azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors, a mouse model for colitis-associated colorectal cancers in humans. Contrary to expectations, Bcl-3 suppressed colorectal tumor formation: Bcl-3-deficient mice were relatively protected from DSS-induced epithelial damage and developed more polyps after AOM/DSS treatment, although polyp size was unaffected. DSS-challenged mutant mice exhibited increased recruitment of myeloid-derived suppressor cells, consistent with protection of the epithelium. Loss of Bcl-3 in intestinal epithelial cells was sufficient to increase tumorigenesis. The added tumor burden in mutant mice was dependent on tumor necrosis factor-α (TNFα), a tumorigenic, NF-κB-mediated signaling pathway that was dampened by Bcl-3. These findings reveal a tumor-suppressive role for Bcl-3 in this inflammation-associated cancer model. Bcl-3 thus functions as a tumor promoter or suppressor, depending on the cellular and environmental context.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hayden MS, Ghosh S . NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26: 203–234.
Siebenlist U, Brown K, Claudio E . Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 2005; 5: 435–445.
Hinz M, Arslan SC, Scheidereit C . It takes two to tango: IkappaBs, the multifunctional partners of NF-kappaB. Immunol Rev 2012; 246: 59–76.
Palmer S, Chen YH . Bcl-3, a multifaceted modulator of NF-kappaB-mediated gene transcription. Immunol Res 2008; 42: 210–218.
Schuster M, Annemann M, Plaza-Sirvent C, Schmitz I . Atypical IkappaB proteins - nuclear modulators of NF-kappaB signaling. Cell Commun Signal 2013; 11: 23.
Maldonado V, Melendez-Zajgla J . Role of Bcl-3 in solid tumors. Mol Cancer 2011; 10: 152.
Kashatus D, Cogswell P, Baldwin AS . Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 2006; 20: 225–235.
Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R . Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665–677.
Liu Z, Jiang Y, Hou Y, Hu Y, Cao X, Tao Y et al. The IkappaB family member Bcl-3 stabilizes c-Myc in colorectal cancer. J Mol Cell Biol 2013; 5: 280–282.
Wakefield A, Soukupova J, Montagne A, Ranger J, French R, Muller WJ et al. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. Cancer Res 2013; 73: 745–755.
Grivennikov SI . Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013; 35: 229–244.
De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J Carcinog 2011; 10: 9.
Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560–570.
Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828–831.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285–296.
Burkitt MD, Hanedi AF, Duckworth CA, Williams JM, Tang JM, O'Reilly LA et al. NF-kappaB1, NF-kappaB2 and c-Rel differentially regulate susceptibility to colitis-associated adenoma development in C57BL/6 mice. J Pathol 2015; 236: 326–336.
Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103–113.
Tassi I, Rikhi N, Claudio E, Wang H, Tang W, Ha HL et al. The NF-kappaB regulator Bcl-3 modulates inflammation during contact hypersensitivity reactions in radioresistant cells. Eur J Immunol 2015; 45: 1059–1068.
Tang W, Wang H, Claudio E, Tassi I, Ha HL, Saret S et al. The oncoprotein and transcriptional regulator Bcl-3 governs plasticity and pathogenicity of autoimmune T cells. Immunity 2014; 41: 555–566.
O'Carroll C, Moloney G, Hurley G, Melgar S, Brint E, Nally K et al. Bcl-3 deficiency protects against dextran-sodium sulphate-induced colitis in the mouse. Clin Exp Immunol 2013; 173: 332–342.
Nielsen OH . New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne) 2014; 1: 3.
Onizawa M, Nagaishi T, Kanai T, Nagano K, Oshima S, Nemoto Y et al. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G850–G859.
Naito Y, Takagi T, Handa O, Ishikawa T, Nakagawa S, Yamaguchi T et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 2003; 18: 560–569.
Pene F, Paun A, Sonder SU, Rikhi N, Wang H, Claudio E et al. The IkappaB family member Bcl-3 coordinates the pulmonary defense against Klebsiella pneumoniae infection. J Immunol 2011; 186: 2412–2421.
Tassi I, Claudio E, Wang H, Tang W, Ha HL, Saret S et al. The NF-kappaB regulator Bcl-3 governs dendritic cell antigen presentation functions in adaptive immunity. J Immunol 2014; 193: 4303–4311.
Diaz-Montero CM, Finke J, Montero AJ . Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 2014; 41: 174–184.
Manjili MH, Wang XY, Abrams S . Evolution of our understanding of myeloid regulatory cells: from MDSCs to Mregs. Front Immunol 2014; 5: 303.
Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN . CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013; 24: 631–644.
Pasparakis M . Role of NF-kappaB in epithelial biology. Immunol Rev 2012; 246: 346–358.
Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91–102.
Franzoso G, Carlson L, Scharton-Kersten T, Shores EW, Epstein S, Grinberg A et al. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity 1997; 6: 479–490.
Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 1998; 187: 147–159.
Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD . The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32: 379–391.
Eigenbrod T, Bode KA, Dalpke AH . Early inhibition of IL-1beta expression by IFN-gamma is mediated by impaired binding of NF-kappaB to the IL-1beta promoter but is independent of nitric oxide. J Immunol 2013; 190: 6533–6541.
Acknowledgements
We greatly appreciate the constructive inputs provided by all members of the Siebenlist laboratory. This research was supported by the Intramural Research Program of NIAID, NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Tang, W., Wang, H., Ha, H. et al. The B-cell tumor promoter Bcl-3 suppresses inflammation-associated colon tumorigenesis in epithelial cells. Oncogene 35, 6203–6211 (2016). https://doi.org/10.1038/onc.2016.152
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2016.152
This article is cited by
-
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age
Molecular Cancer (2024)
-
Bcl-3 promotes Wnt signaling by maintaining the acetylation of β-catenin at lysine 49 in colorectal cancer
Signal Transduction and Targeted Therapy (2020)
-
Elevated levels of Bcl-3 inhibits Treg development and function resulting in spontaneous colitis
Nature Communications (2017)